Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cybin Inc. (CYBN)

NYSE American - NYSE American Delayed Price. Currency in USD
0.43000.0000 (0.00%)
At close: 01:00PM EST
0.4394 +0.01 (+2.19%)
After hours: 04:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4300
Open0.4300
Bid0.4229 x 800
Ask0.4392 x 900
Day's Range0.4180 - 0.4400
52 Week Range0.3900 - 1.6000
Volume334,053
Avg. Volume1,017,052
Market Cap69.651M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3080
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.47
  • Business Wire

    Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

    TORONTO, November 15, 2022--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience ("SFN") taking place November 12-16, 2022, in San Diego, CA.

  • Business Wire

    Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights

    TORONTO, November 14, 2022--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights.

  • Business Wire

    Cybin Provides Progress Update on its CYB004-E Phase 1 Trial

    TORONTO, November 10, 2022--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce that its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine ("DMT") has completed dosing for four out of five participant cohorts and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The CYB004-E Phase 1 trial was acquired from Entheon Biom

Advertisement
Advertisement